|
|
|
|
Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques
|
|
|
|
|
|
|
|
نویسنده
|
broeckel r. ,fox j.m. ,haese n. ,kreklywich c.n. ,sukulpovi-petty s. ,legasse a. ,smith p.p. ,denton m. ,corvey c. ,krishnan s. ,colgin l.m.a. ,ducore r.m. ,lewis a.d. ,axthelm m.k. ,mandron m. ,cortez p. ,rothblatt j. ,rao e. ,focken i. ,carter k. ,sapparapau g. ,crowe j.e. ,diamond m.s. ,streblow d.n.
|
|
منبع
|
plos neglected tropical diseases - 2017 - دوره : 11 - شماره : 6
|
|
چکیده
|
Chikungunya virus (chikv) is a mosquito-borne virus that causes a febrile syndrome in humans associated with acute and chronic debilitating joint and muscle pain. currently no licensed vaccines or therapeutics are available to prevent or treat chikv infections. we recently isolated a panel of potently neutralizing human monoclonal antibodies (mabs),one (4n12) of which exhibited prophylactic and post-exposure therapeutic activity against chikv in immunocompromised mice. here,we describe the development of an engineered chikv mab,designated svir001,that has similar antigen binding and neutralization profiles to its parent,4n12. because therapeutic administration of svir001 in immunocompetent mice significantly reduced viral load in joint tissues,we evaluated its efficacy in a rhesus macaque model of chikv infection. rhesus macaques that were treated after infection with svir001 showed rapid elimination of viremia and less severe joint infiltration and disease compared to animals treated with svir002,an isotype control mab. svir001 reduced viral burden at the site of infection and at distant sites and also diminished the numbers of activated innate immune cells and levels of pro-inflammatory cytokines and chemokines. svir001 therapy; however,did not substantively reduce the induction of chikv-specific b or t cell responses. collectively,these results show promising therapeutic activity of a human anti-chikv mab in rhesus macaques and provide proof-of-principle for its possible use in humans to treat active chikv infections. © 2017 broeckel et al.
|
|
|
|
|
آدرس
|
vaccine and gene therapy institute,oregon health and science university,beaverton, United States, departments of medicine,molecular microbiology,pathology & immunology,washington university school of medicine,st. louis, United States, vaccine and gene therapy institute,oregon health and science university,beaverton, United States, vaccine and gene therapy institute,oregon health and science university,beaverton, United States, departments of medicine,molecular microbiology,pathology & immunology,washington university school of medicine,st. louis, United States, division of pathobiology and immunology,oregon national primate research center,beaverton, United States, vaccine and gene therapy institute,oregon health and science university,beaverton, United States, vaccine and gene therapy institute,oregon health and science university,beaverton, United States, sanofi,cambridge, United States, sanofi,cambridge, United States, pathology services unit,division of comparative medicine,oregon national primate research center,beaverton, United States, pathology services unit,division of comparative medicine,oregon national primate research center,beaverton, United States, pathology services unit,division of comparative medicine,oregon national primate research center,beaverton, United States, vaccine and gene therapy institute,oregon health and science university,beaverton,united states,division of pathobiology and immunology,oregon national primate research center,beaverton, United States, sanofi,marcy l’etoile, France, sanofi,marcy l’etoile, France, sanofi,cambridge, United States, sanofi,marcy l’etoile, France, sanofi,marcy l’etoile, France, sanofi,cambridge, United States, departments of pediatrics and pathology,microbiology,and immunology,vanderbilt university,nashville, United States, jr.,departments of pediatrics and pathology,microbiology,and immunology,vanderbilt university,nashville, United States, departments of medicine,molecular microbiology,pathology & immunology,washington university school of medicine,st. louis, United States, vaccine and gene therapy institute,oregon health and science university,beaverton,united states,division of pathobiology and immunology,oregon national primate research center,beaverton, United States
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|